Latest News and Press Releases
Want to stay updated on the latest news?
-
ALLSCHWIL and BASEL, Switzerland, Dec. 15, 2003 (PRIMEZONE) -- Actelion: -- Reimbursement status achieved in Australia -- Labeling questions received from Japanese regulator -- Limited...
-
ALLSCHWIL/BASEL, Switzerland and WHITEHOUSE STATION, N.J., Dec. 04, 2003 (PRIMEZONE) -- Actelion: -- Actelion to advance its break-through discoveries of new classes of renin inhibitors...
-
ALLSCHWIL/BASEL, Switzerland, Oct. 29, 2003 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) today provided a comprehensive overview of its preclinical and clinical pipeline at its R&D Day in London (UK)....
-
ALLSCHWIL/BASEL, Switzerland, Oct. 28, 2003 (PRIMEZONE) -- Actelion (SWX:ATLN) (Other OTC:ALIOF) -- Strong Tracleer(R) sales in Pulmonary Arterial Hypertension result in an operating profit...
-
ALLSCHWIL, Switzerland, Oct. 23, 2003 (PRIMEZONE) -- Actelion announces the 9 months 2003 results on 28th October 2003. Actelion Research and Development Day 2003 on 29th October 2003 Dear Friend...
-
ALLSCHWIL/BASEL, Switzerland, Sept. 30, 2003 (PRIMEZONE) -- - Actelion to further develop intravenous endothelin receptor antagonist optimized for cerebral indications currently in Phase...
-
ALLSSHWIL, Switzerland, Sept. 02, 2003 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) (Other OTC:ALIOF) today announced results of a study assessing its oral dual endothelin receptor antagonist (ERA)...
-
ALLSCHWIL/BASEL, July 31, 2003 (PRIMEZONE) -- Actelion Ltd (SWX: ATLN) today announced that the US Food and Drug Administration (FDA) has approved Zavesca(r) (miglustat) capsules the first oral...
-
ALLSCHWIL/BASEL, Switzerland, June 17, 2003 (PRIMEZONE) -- Actelion Ltd. (SWX:ATLN) and privately held Axovan AG announced today that they have entered into a research collaboration. The two...
-
ALLSCHWIL/BASEL, Switzerland/SAN DIEGO, , June 02, 2003 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) and Discovery Partners International, Inc. (Nasdaq:DPII) today announced that the two companies have...